Low Expression Of Apaf-1xl In Acute Myeloid Leukemia May Be Associated With The Failure Of Remission Induction Therapy.

dc.creatorBenites, B D
dc.creatorFattori, A
dc.creatorHackel, C
dc.creatorLorand-Metze, I
dc.creatorDe Souza, C A
dc.creatorSchulz, E
dc.creatorCosta, F F
dc.creatorSaad, S T O
dc.date2008-Jul
dc.date2015-11-27T13:13:08Z
dc.date2015-11-27T13:13:08Z
dc.date.accessioned2018-03-29T01:07:23Z
dc.date.available2018-03-29T01:07:23Z
dc.identifierBrazilian Journal Of Medical And Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas / Sociedade Brasileira De Biofísica ... [et Al.]. v. 41, n. 7, p. 571-8, 2008-Jul.
dc.identifier1414-431X
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/18719738
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/197946
dc.identifier18719738
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1298179
dc.descriptionApoptotic protease activating factor 1 (APAF-1) has a critical role in the regulation of apoptosis. In the present study, the mRNA expression analysis of different APAF-1 transcripts (APAF-1S, APAF-1LC, APAF-1LN, and APAF-1XL) was analyzed in bone marrow samples from 37 patients with acute myeloid leukemia (newly diagnosed, with no previous treatment). APAF-1XL and APAF-1LN transcripts (with and without an extra WD-40 repeat region, respectively) were detected in all samples, although the major form expressed was APAF-1XL in 65% of the samples (group 1), while 35% of the samples expressed primarily APAF-1LN (group 2). Only 46% of the patients presented complete remission in response to remission induction therapy (represented by less than 5% marrow blasts and hematological recovery), all but 2 cases being from group 1, 21.6% did not attain complete remission (only 1 case from group 1), and 32.4% of the patients died early. Lower expression of APAF-1XL (APAF-1XL/APAF-1LN ratio <1.2) was associated with a poor response to therapy (P = 0.0005, Fisher exact test). Both groups showed similar characteristics regarding white blood cell counts, cytogenetic data or presence of gene rearrangements associated with good prognosis as AML1-ETO, CBFB-MYH11 and PML/RARA. Since it has been shown that only the isoforms with the extra WD-40 repeat region activate procaspase-9, we suggest that low procaspase-9 activation may also be involved in the deregulation of apoptosis and chemotherapy resistance in acute myeloid leukemia.
dc.description41
dc.description571-8
dc.languageeng
dc.relationBrazilian Journal Of Medical And Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas / Sociedade Brasileira De Biofísica ... [et Al.]
dc.relationBraz. J. Med. Biol. Res.
dc.rightsaberto
dc.rights
dc.sourcePubMed
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 And Over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectApoptotic Protease-activating Factor 1
dc.subjectBone Marrow Cells
dc.subjectCase-control Studies
dc.subjectDna, Complementary
dc.subjectDensitometry
dc.subjectFemale
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectLeukemia, Myeloid, Acute
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRna, Messenger
dc.subjectReverse Transcriptase Polymerase Chain Reaction
dc.subjectTranscription Factors
dc.subjectTranscription, Genetic
dc.subjectTreatment Failure
dc.subjectTumor Markers, Biological
dc.subjectYoung Adult
dc.titleLow Expression Of Apaf-1xl In Acute Myeloid Leukemia May Be Associated With The Failure Of Remission Induction Therapy.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución